Education
About Us
Working with TipRanks
Follow Us
NewAmsterdam Pharma Company (NAMS)
NASDAQ:NAMS
NAMS Stock Chart & Stats
$35.84
-$0.03(-0.12%)
At close: 4:00 PM EST
$35.84
-$0.03(-0.12%)
Day’s Range― - ―
52-Week Range$14.06 - $41.47
Previous CloseN/A
Volume118.30K
Average Volume (3M)1.18M
Market Cap
$4.04B
Enterprise Value$1.41B
Total Cash (Recent Filing)$739.16M
Total Debt (Recent Filing)$328.00K
Price to Earnings (P/E)―
Beta1.79
Next Earnings
Nov 17, 2025EPS Estimate
-0.39Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.15
Shares Outstanding112,628,456
10 Day Avg. Volume1,328,056
30 Day Avg. Volume1,175,835
Financial Highlights & Ratios
PEG Ratio-0.53
Price to Book (P/B)3.20
Price to Sales (P/S)53.22
P/FCF Ratio-15.23
Enterprise Value/Market Cap0.35
Enterprise Value/Revenue22.00
Enterprise Value/Gross Profit22.00
Enterprise Value/Ebitda-5.87
Forecast
1Y Price Target
$43.22Price Target Upside20.59% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering11
Bulls Say, Bears Say
Bulls Say
Alzheimer's DiseaseObi leads to statistically significant and clinically meaningful reductions in p-tau217, a biomarker associated with Alzheimer's disease.
Cardiovascular BenefitsAn exploratory endpoint analysis from BROADWAY demonstrated a 21% reduction in the occurrence of 4-point major adverse cardiovascular events (MACE), indicating potential for CV benefits beyond LDL-C.
Clinical TrialsObicetrapib has exhibited significant LDL-C reductions vs. placebo in multiple Phase 3 trials, alone or in combination with ezetimibe, as an adjunct to statin therapy.
Bears Say
NewAmsterdam Pharma Company News
NAMS FAQ
What was NewAmsterdam Pharma Company’s price range in the past 12 months?
NewAmsterdam Pharma Company lowest stock price was $14.06 and its highest was $41.47 in the past 12 months.
What is NewAmsterdam Pharma Company’s market cap?
NewAmsterdam Pharma Company’s market cap is $4.04B.
When is NewAmsterdam Pharma Company’s upcoming earnings report date?
NewAmsterdam Pharma Company’s upcoming earnings report date is Nov 17, 2025 which is in 17 days.
How were NewAmsterdam Pharma Company’s earnings last quarter?
NewAmsterdam Pharma Company released its earnings results on Aug 06, 2025. The company reported -$0.15 earnings per share for the quarter, beating the consensus estimate of -$0.463 by $0.313.
Is NewAmsterdam Pharma Company overvalued?
According to Wall Street analysts NewAmsterdam Pharma Company’s price is currently Undervalued.
Does NewAmsterdam Pharma Company pay dividends?
NewAmsterdam Pharma Company does not currently pay dividends.
What is NewAmsterdam Pharma Company’s EPS estimate?
NewAmsterdam Pharma Company’s EPS estimate is -0.39.
How many shares outstanding does NewAmsterdam Pharma Company have?
NewAmsterdam Pharma Company has 112,628,456 shares outstanding.
What happened to NewAmsterdam Pharma Company’s price movement after its last earnings report?
NewAmsterdam Pharma Company reported an EPS of -$0.15 in its last earnings report, beating expectations of -$0.463. Following the earnings report the stock price went up 8.698%.
Which hedge fund is a major shareholder of NewAmsterdam Pharma Company?
Currently, no hedge funds are holding shares in NAMS
NewAmsterdam Pharma Company Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$43.22 (20.59% Upside)
$43.22 (20.59% Upside)
Blogger Sentiment
Bullish
NAMS Sentiment 100%
Sector Average 71%
Sector Average 71%
Hedge Fund Trend
Increased
By 1.5M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $6.9M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 2.5%
Last 30 Days ▼ 2.5%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
88.90%
12-Months-Change
Fundamentals
Return on Equity
-28.43%
Trailing 12-Months
Asset Growth
82.48%
Trailing 12-Months
Company Description
NewAmsterdam Pharma Company
NewAmsterdam Pharma Company (NAMS) is a biopharmaceutical company focused on developing innovative therapies for metabolic diseases, particularly in the areas of dyslipidemia and cardiovascular conditions. The company is dedicated to advancing novel drug candidates that aim to improve patient outcomes and address unmet medical needs. NAMS operates primarily in the pharmaceutical sector, leveraging cutting-edge research and development to create and commercialize its core products, which include therapies designed to manage cholesterol levels and reduce cardiovascular risk.
NAMS Stock 12 Month Forecast
Average Price Target
$43.22
▲(20.59% Upside)
Technical Analysis
Viking Therapeutics
―
Xenon
―
Soleno Therapeutics
―
Kiniksa Pharmaceuticals
―
Immunovant
―
Ownership Overview
16.18% Insiders
16.54% Mutual Funds
0.02% Other Institutional Investors
65.99% Public Companies and
Individual Investors